{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:04:24Z","timestamp":1792605864636,"version":"4.5.0"},"reference-count":46,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["GNT1000896 and 1020555"],"award-info":[{"award-number":["GNT1000896 and 1020555"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014989","name":"Chan Zuckerberg Initiative","doi-asserted-by":"publisher","award":["2020-217531 and 2021-237883"],"award-info":[{"award-number":["2020-217531 and 2021-237883"]}],"id":[{"id":"10.13039\/100014989","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,1,25]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic fibrosis (CF) lung disease. Despite this, no CF-specific anti-inflammatory treatments have been developed. This is crucial even in the era of highly effective modulator therapy as recent evidence suggests that modulators alter, but may not fully resolve, pulmonary inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we used clinical microbiology data, high-dimensional flow cytometry and multiplex immunoassays to compare pulmonary (bronchoalveolar lavage (BAL)) and systemic immunity in 70 preschool children with CF and a total of 32 age-matched preschool controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We show that inflammation in the early-life CF lung is characterised by innate cell infiltration (neutrophils: 31.31 vs 1.8% of BAL in CF compared with controls, FDRp=0.0001; eosinophils: 0.55 vs 0.06%, FDRp=0.001, and monocytes: 1.91 vs 0.45%, FDRp=0.004) and widespread upregulation of both traditional and type 2 inflammatory soluble signatures (40 analytes significantly elevated in BAL of CF compared with controls, all FDRp&lt;0.1). Key targetable features of this response included pulmonary interleukin (IL)-8 and IL-13 which were most significantly associated with neutrophilic and eosinophilic infiltration, respectively (IL-8 and neutrophils; Spearman rho=0.68, FDRp=0.002: IL-13 and eosinophils; Spearman rho=0.75, FDRp=0.01). Signatures of type 2 inflammation, as identified by REACTOME pathway analysis, including IL-4, IL-13 and FGF-2, were highly elevated in both the lungs and circulation in early CF. When exploring the efficacy of Cystic Fibrosis Transmembrane Conductance Regulator modulators to resolve pulmonary and systemic inflammation in early life, we showed that different classes of modulators have varying effects on inflammation, with ivacaftor showing a more significant effect in the lungs and circulation than lumacaftor\/ivacaftor. Finally, we showed that CF children with pathogen colonisation had similar levels of pulmonary inflammation as CF children without pathogen colonisation (no significant differences), and that inflammation was evident during infancy even without evidence of colonisation (as observed by significant increases in levels of SDF-1alpha, M-CSF, IL-2, IL-9, IL-12p40, IL-17, MCP-1 and LIGHT\/TNFSF14, all FDRp&lt;0.1), highlighting a role for intrinsic dysregulation of inflammation that begins in early life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We provide a rationale for targeted anti-inflammatory intervention in early-life CF.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thorax-2024-221634","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T18:20:33Z","timestamp":1739211633000},"page":"433-444","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators"],"prefix":"10.1136","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6000-3180","authenticated-orcid":false,"given":"Shivanthan","family":"Shanthikumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Gubbels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anson Tsz Chun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-0307","authenticated-orcid":false,"given":"Sarath C","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7301-9982","authenticated-orcid":false,"given":"Melanie R","family":"Neeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2025061605400850000_80.7.433.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3"},{"key":"2025061605400850000_80.7.433.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301725"},{"key":"2025061605400850000_80.7.433.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201606-1107CI"},{"key":"2025061605400850000_80.7.433.4","unstructured":"Cystic Fibrosis Foundation . Drug development pipeline. 2023. Available: https:\/\/apps.cff.org\/trials\/pipeline [Accessed 20 Sep 2023]."},{"key":"2025061605400850000_80.7.433.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01609-4"},{"key":"2025061605400850000_80.7.433.6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"2025061605400850000_80.7.433.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-018-1396-2","article-title":"A standardized framework for representation of ancestry data in genomics studies, with application to the NHGRI-EBI GWAS Catalog","volume":"19","author":"Morales","year":"2018","journal-title":"Genome Biol"},{"key":"2025061605400850000_80.7.433.8","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1387","article-title":"Off-target effects of bacillus Calmette-Gu\u00e9rin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19","volume":"11","author":"Messina","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"2025061605400850000_80.7.433.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1585OC"},{"key":"2025061605400850000_80.7.433.10","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","article-title":"The Reactome Pathway Knowledgebase 2024","volume":"52","author":"Milacic","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2025061605400850000_80.7.433.11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1131"},{"key":"2025061605400850000_80.7.433.12","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.4.96-11058"},{"key":"2025061605400850000_80.7.433.13","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.5.9805028"},{"key":"2025061605400850000_80.7.433.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70116-8"},{"key":"2025061605400850000_80.7.433.15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733217","article-title":"Mapping Pulmonary and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis","volume":"12","author":"Shanthikumar","year":"2021","journal-title":"Front Immunol"},{"key":"2025061605400850000_80.7.433.16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbadis.2010.04.005","article-title":"Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis","volume":"1802","author":"McGreal","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2025061605400850000_80.7.433.17","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20010"},{"key":"2025061605400850000_80.7.433.18","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.7.2010139"},{"key":"2025061605400850000_80.7.433.19","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1144"},{"key":"2025061605400850000_80.7.433.20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.3.638"},{"key":"2025061605400850000_80.7.433.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00178508"},{"key":"2025061605400850000_80.7.433.22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1183\/16000617.0001-2024","article-title":"Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target","volume":"33","author":"Mall","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2025061605400850000_80.7.433.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01050-2024"},{"key":"2025061605400850000_80.7.433.24","unstructured":"Stahl M . A study to evaluate safety and efficacy of subcutaneous administration of anakinra in patients with CF (ANAKIN). 2022. Available: https:\/\/clinicaltrials.gov\/study\/NCT03925194"},{"key":"2025061605400850000_80.7.433.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055137"},{"key":"2025061605400850000_80.7.433.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-012-9393-9"},{"key":"2025061605400850000_80.7.433.27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051730","article-title":"Concomitant Use of Elexacaftor\/Tezacaftor\/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis","volume":"12","author":"Orsini","year":"2023","journal-title":"J Clin Med"},{"key":"2025061605400850000_80.7.433.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951"},{"key":"2025061605400850000_80.7.433.29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01333-2019","article-title":"Anti-IL5 and anti-IL5R\u03b1 therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series","volume":"55","author":"Rademacher","year":"2020","journal-title":"Eur Respir J"},{"key":"2025061605400850000_80.7.433.30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/pai.13619","article-title":"Type 2 inflammation in cystic fibrosis: New insights","volume":"33 Suppl 27","author":"Manti","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"2025061605400850000_80.7.433.31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176109"},{"key":"2025061605400850000_80.7.433.32","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26063"},{"key":"2025061605400850000_80.7.433.33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.642180","article-title":"Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid","volume":"12","author":"Mainz","year":"2021","journal-title":"Front Immunol"},{"key":"2025061605400850000_80.7.433.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202210-1938LE"},{"key":"2025061605400850000_80.7.433.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202401-0201LE"},{"key":"2025061605400850000_80.7.433.36","doi-asserted-by":"publisher","DOI":"10.1177\/1179559X17719123"},{"key":"2025061605400850000_80.7.433.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201004-0643OC"},{"key":"2025061605400850000_80.7.433.38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000928","article-title":"Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth","volume":"2","author":"Stoltz","year":"2010","journal-title":"Sci Transl Med"},{"key":"2025061605400850000_80.7.433.39","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.23.2.4214"},{"key":"2025061605400850000_80.7.433.40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201708-1616OC"},{"key":"2025061605400850000_80.7.433.41","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.4.7697234"},{"key":"2025061605400850000_80.7.433.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201011-1892OC"},{"key":"2025061605400850000_80.7.433.43","article-title":"Cardiovascular System Involvement in Cystic Fibrosis","volume":"13","author":"Shah","year":"2021","journal-title":"Cureus"},{"key":"2025061605400850000_80.7.433.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.04.016"},{"key":"2025061605400850000_80.7.433.45","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-022-00030-y"},{"key":"2025061605400850000_80.7.433.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.10.018"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-221634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:40:51Z","timestamp":1750077651000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-221634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/thorax-2024-221634"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-221634","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}